Close Menu

This week in PLoS One, researchers report that missense mutations in FMR1 are not a cause of the Fragile X syndrome phenotype in patients who have normal-length CGG-repeat expansions. To decipher this, the team used an array-based method to sequence FMR1 in 51 individuals exhibiting features of FXS with normal CGG-repeat tracts of the gene. The team suggests that "screening for small deletions of FMR1 may be of clinically utility."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.